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medical resource use, impact on productivity for both patients and carers, and
detrimental effects on education and careers.
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OBJECTIVES: Idiopathic Pulmonary Fibrosis (IPF) is a rare, irreversible and eventu-
ally fatal fibrosing lung disease. Cough and dyspnea are major symptoms. The
study objective was to assess the content validity of the Cough and Sputum As-
sessment Questionnaire (CASA-Q) cough domains and the UCSD Shortness of
Breath Questionnaire (SOBQ), instruments developed for use in chronic obstructive
pulmonary disease, when used in patients with IPF. METHODS: Cross-sectional,
qualitative study with cognitive interviews in patients with IPF. Study outcomes
included relevance, comprehension of item meaning, understanding of the in-
structions, recall period, response options, and concept saturation. RESULTS: In-
terviews were conducted with 18 patients. The mean age was 68.9 years (SD 11.9),
78% were male and 89% were Caucasian. The mean time since IPF diagnosis was 2.4
years (SD 1.6). Most participants (89%) found the CASA-Q cough domain items to be
highly relevant to their condition. The intended meaning of the items was clearly
understood by most of the participants (89-100%). All participants understood the
CASA-Q instructions; the correct recall period was reported by 89% of the patients,
and the response options were understood by 76%. Most participants (83%) re-
ported positive feedback for the SOBQ; those who did not were symptom free and
hence had no limitation in activities to report. The intended meanings of the items
were relevant and clearly understood by all participants. Participants understood
the instructions (83%) and all patients understood the response options. The recall
period produced varying responses, based on the type of activity performed. No
concepts were missing, suggesting that saturation was demonstrated for both
measures. CONCLUSIONS: Content validity and saturation for the CASA-Q cough
domain and SOBQ was established with items perceived as relevant to measure
symptoms of IPF. The results of this study support the use of these instruments in
IPF clinical trials.
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OBJECTIVES: To evaluate disease-specific quality of life (QoL) in children with
asthma according to patients’ and their parents’ perspective. METHODS: Hungar-
ian version of the Standardised Paediatric Asthma Quality of Life Questionnaire
(PAQLQ(s)) and the Paediatric Asthma Caregiver’s Quality of Life Questionnaire (PACQLQ)
were completed. The minimal important difference in the PAQLQ total score is 0.5
on the 7-point Likert scale, higher scores indicate better QoL. Asthma control was
assessed by Asthma Control Questionnaire (ACQ); Forced Expiratory Volume in 1 sec-
ond (FEV1) was measured via spirometry. RESULTS: A total of 125 children (7-17
years of age) and their caregivers completed the questionnaires. Overall PAQLQ
score was 5.740.97, overall PACQLQ score was 5.321.22 (r0.83), mean ACQ score
was 1.650.8 and mean FEV1 was 100.7114.91. PACQLQ scores were statistically
(p0.001) and clinically significantly lower, than PAQLQ scores. Correlations be-
tween FEV1 and overall score of PAQLQ(s) (r-0.15) and overall PACQLQ score (r-
0.005) were weak and not significant. The association between ACQ and total score
of PAQLQ(s)(r-0.64, p0.01) was moderate. CONCLUSIONS: Our participants had
poor asthma control despite their good lung function. Weak relationship was found
between spirometry and QoL according to patients’ and caregivers’ opinion; how-
ever QoL correlated only moderately with the level of asthma control. PAQLQ is able
to detect small but clinically important changes that children experience as a result
of the treatment or as a part of the natural fluctuation of their asthma, it provides
additional valuable information for clinical practice; children aged over 7 can pro-
vide reliable data on their Qol, where as parents often do not rate their children’s
Qol appropriately.
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OBJECTIVES: The Smoking Cessation Quality of Life (SCQoL) questionnaire as-
sesses the change in well-being and functioning associated with smoking cessa-
tion. The SCQoL includes 14 questions. This study aims to adapt the SCQoL into
Turkish language and culture and, check the reliability and validity of the inven-
tory culturally. METHODS: The original instrument was forward then back-trans-
lated by two independent translators. A small sample consisting of 42 people was
used to check the initial comprehension and convenance. Cronbach’s Alpha was
used to assess reliability and factor analysis to assess dimensionality. The Euro-
Qol-5D questionnaire and corresponding Visual Analogue Scales were used for
concurrent validity.RESULTS:A total of 152 people participated in this study. 55.9%
of them were female, 44.1% of them being male. Mean age was 24.3. The internal
consistency coefficient (Cronbach’s alpha) of SCQoL was 0.771. Factor analysis of
the scale revealed that it was composed of four factors and accounting for 67% of
the total variance. Correlations were moderate with EuroQol and VAS.
CONCLUSIONS: The culturally adapted to Turkish SCQoL has good validity and
reliability, making it a potentially useful outcome measure in determining the
effect of quality of life of people in Turkey.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic, debilitating dis-
ease characterized by an increase in blood pressure in the pulmonary arteries and
is associated with a burdensome low tolerance to exercise. Treprostinil is indicated
in the treatment of PAH in patients with New York Heart Association Class II-IV
symptoms and is available in one of two forms: infused or inhaled. The present
study determined the preference among members of the general public for one
treatment delivery option over the other, as well as the willingness-to-pay (WTP)
for the inhaled option. METHODS: An online survey of members of the general
public, 18 years of age or older, in the province Ontario, Canada, was conducted by
presenting descriptive and clinical information on each treatment delivery option,
ascertaining the participants’ preference for one option over the other, and, by
inviting participants who opted for the inhaled form to take part in a bidding game
evaluating their WTP in terms of additional monthly insurance premiums to en-
sure that inhaled treprostinil would be covered by a hypothetical insurance
scheme. Descriptive statistics and sub-group analyses based on demographic char-
acteristics were calculated with regards to preference and WTP. RESULTS: The
recruited population was more likely to be female, younger and with a higher
yearly household income, when compared to the population of Ontario. Of the 386
survey participants, 85.8% preferred the inhaled treatment option, with no signif-
icant differences in terms of preference observed across age or gender. The ob-
served median (minimum, maximum, mode) and mean (95% confidence interval)
WTP in monthly insurance premiums were CAD21.50 (CAD0, CAD200, CAD50) and
CAD37.25 (CAD32.51, CAD41.99), respectively; sub-group analyses based on gender,
age or yearly household income yielded no significant differences. CONCLUSIONS:
Inhaled treprostinil appears to be preferred over infused treprostinil and is associ-
ated with relatively high WTP for insurance premiums.
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OBJECTIVES: Pharmaceutical companies are increasingly shifting from a product-
centered to a customer and service-centered culture and many companies have
developed disease management programs for illnesses like asthma, COPD, diabe-
tes, arthritis, depression etc. Such programs come in all shapes and sizes and their
main aim is to improve the quality of care are reduce hospital costs. However, there
is insufficient evidence of cost-effectiveness of disease management programs.
Aim: The aim of this study is to review the impact of COPD disease management
(COPD-DM) programs on health care costs and outcomes. We also investigated the
impact of disease-, intervention-, and study-characteristics. METHODS: We con-
ducted a systematic review of cost-effectiveness studies of COPD-DM. The results
were grouped by study, intervention and disease characteristics and, where feasi-
ble, included in a random-effects meta-analysis. RESULTS: We included 16 papers
describing 11 studies. The meta-analysis showed that COPD-DM decreased the RR
of hospitalizations (RR: 0.71 [95CI: 0.53-0.96]), and led to a reduction of hospitaliza-
tion costs (€1093 [95CI: €2052-€133]) and average health care savings were €922
[95CI: €1549-€295] per patient. These savings have to be weighed against the costs
of developing, implementing and managing the DM program. There was substan-
tial heterogeneity. DM showed greater savings in hospital costs in studies including
severe COPD patients (GOLD stage 3). Savings were also greater when COPD-DM
programs addressed 3 or more components of the Chronic Care Model and in
studies from non-EU origin. CONCLUSIONS: DM decreased the risk of hospitaliza-
tion and health care costs (excluding program costs), but results varied by study-,
intervention-, and disease-characteristics. Future studies should more explicitly
include the overhead costs of running these DM programs.
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OBJECTIVES: Respiratory Syncytial virus (RSV) is the leading cause of respiratory
tract infections. Efficacy of Palivizumab in reducing RSV related hospitalizations
has been proven in preterm born infants and children with congenital heart dis-
ease (CHD) or bronchopulmonary dysplasia (BPD). However, the high costs of
Palivizumab may limit its use. This study described the characteristics of Palivi-
zumab users in the Netherlands and assessed the determinants of receiving Palivi-
zumab among infants with an indication according to the label. METHODS: Data
for this study were obtained by linking the PHARMO database network, which
includes detailed information on drug dispensing and hospitalization histories,
and The Netherlands Perinatal Registry, including perinatal medical case records.
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